Hypothesis

Transient senescent cells function as metabolic chaperones that export lactate to neighboring stromal and epithelial cells, thereby sustaining a local lactate gradient that promotes myofibroblast differentiation and angiogenic signaling during acute wound repair. Chronic senescent cells lose this lactate‑exporting capacity and instead secrete pathological SASP factors (e.g., FasL, IL‑6) that impair tissue homeostasis. Consequently, senolytic ablation of all senescent cells removes a beneficial lactate‑shuttle, delaying wound healing and disrupting barrier integrity, whereas SASP reprogramming that preserves lactate export restores repair.

Mechanistic Reasoning

• Lactate is a known signaling metabolite that stabilizes HIF‑1α, drives PDGF‑AA secretion, and modulates macrophage polarization toward a pro‑repair phenotype (Lactate signaling in wound healing).
• Senescent fibroblasts already secrete PDGF‑AA to coordinate myofibroblast activation (Sen fibroblasts secrete PDGF‑AA). We propose that lactate secretion is coupled to PDGF‑AA release via a shared monocarboxylate transporter (MCT1/4) axis, creating a dual‑signal microenvironment.
• Persistent senescence is associated with mitochondrial dysfunction that shifts metabolism from glycolysis to oxidative phosphorylation, reducing lactate output while increasing SASP cytokines (Mitochondrial shift in chronic senescence).

Testable Predictions

1. Lactate flux measurement – In vivo lactate sensors will show a transient spike in lactate concentration within the wound margin peaking at days 4‑7 post‑injury, coinciding with the presence of p16^INK4a^+ senescent fibroblasts. Senolytic treatment (e.g., navitoclax) administered at day 3 will blunt this lactate peak.
2. MCT inhibition – Pharmacological blockade of MCT4 in senescent fibroblasts will recapitulate the senolytic phenotype: delayed wound closure, reduced PDGF‑AA deposition, and increased FasL surface expression, despite the senescent cells remaining present.
3. SASP reprogramming – Forcing lactate export in chronic senescent cells (via overexpression of LDHA or MCT4) will shift their secretory profile toward PDGF‑AA and away from FasL, improving barrier function in aged mice without clearing the cells.
4. Rescue experiment – Exogenous lactate supplementation (physiological concentration) will rescue the wound‑healing defect caused by senolytic clearance, mimicking the effect of PDGF‑AA supplementation reported earlier.

Falsifiability

If lactate levels do not rise transiently during wound repair, or if MCT4 inhibition fails to impair wound healing despite senescent cell presence, the lactate‑shuttle hypothesis is falsified. Likewise, if lactate supplementation does not rescue senolytic‑induced healing defects, the proposed metabolic chaperone role is unsupported.

Experimental Outline

• Use p16^INK4a^-GFP reporter mice to isolate transient vs. chronic senescent fibroblasts at defined time points post‑full‑thickness excisional wound.
• Measure extracellular lactate with implanted microdialysis probes and intracellular LDHA/MCT4 expression by flow cytometry and qPCR.
• Apply senolytic, MCT4 inhibitor (e.g., syrosingopine), LDHA overexpression vector (AAV), and lactate injections in factorial design.
• Endpoints: wound area closure rate, histology for α‑SMA and collagen deposition, Evans blue dye leakage for barrier integrity, FasL surface staining.

Potential Impact

Reframing senescent cells as dynamic metabolic chaperones shifts the therapeutic goal from blanket removal to context‑specific modulation of their metabolite‑SASP axis, preserving beneficial transient senescence while mitigating chronic pathology.